Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

Por Guglielmelli, P, Rotunno, G, Fanelli, T, Pacilli, A, Brogi, G, Calabresi, L, Pancrazzi, A, Vannucchi, A M
Publicado no Blood Cancer J (2015)

Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086

Por Cellai, C, Laurenzana, A, Vannucchi, A M, Caporale, R, Paglierani, M, Di Lollo, S, Pancrazzi, A, Paoletti, F
Publicado em 2006

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

Por Tenedini, E, Bernardis, I, Artusi, V, Artuso, L, Roncaglia, E, Guglielmelli, P, Pieri, L, Bogani, C, Biamonte, F, Rotunno, G, Mannarelli, C, Bianchi, E, Pancrazzi, A, Fanelli, T, Malagoli Tagliazucchi, G, Ferrari, S, Manfredini, R, Vannucchi, A M, Tagliafico, E
Publicado em 2014

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neopla...

Por Jovanovic, J V, Ivey, A, Vannucchi, A M, Lippert, E, Oppliger Leibundgut, E, Cassinat, B, Pallisgaard, N, Maroc, N, Hermouet, S, Nickless, G, Guglielmelli, P, van der Reijden, B A, Jansen, J H, Alpermann, T, Schnittger, S, Bench, A, Tobal, K, Wilkins, B, Cuthill, K, McLornan, D, Yeoman, K, Akiki, S, Bryon, J, Jeffries, S, Jones, A, Percy, M J, Schwemmers, S, Gruender, A, Kelley, T W, Reading, S, Pancrazzi, A, McMullin, M F, Pahl, H L, Cross, N C P, Harrison, C N, Prchal, J T, Chomienne, C, Kiladjian, J J, Barbui, T, Grimwade, D
Publicado em 2013